XML 22 R27.htm IDEA: XBRL DOCUMENT v3.19.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2019
USD ($)
$ / shares
shares
Jun. 30, 2018
USD ($)
shares
Jun. 30, 2019
USD ($)
$ / shares
shares
Jun. 30, 2018
USD ($)
shares
Dec. 31, 2018
USD ($)
Patents
Segments
$ / shares
shares
Dec. 31, 2017
USD ($)
$ / shares
shares
Dec. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Restructuring Cost and Reserve [Line Items]                
Common stock, par value | $ / shares $ 0.001   $ 0.001   $ 0.001 $ 0.001    
Warrant liability and embedded derivative liability         $ 623,462 $ 623,462 $ 1,802,375
Amortization method of patents         Straight-line method      
Interest rolled into principal         (30,000)    
Capitalized software development costs         70,231 0    
Advertising costs         3,987 550    
Research and development costs $ 2,608 $ 16,233 $ 6,251 $ 28,429 $ 187,655 $ 128,044    
Anti-dilutive common stock equivalents, excluded from the calculation of earnings per share | shares 48,877,000 42,703,000 48,877,000 42,703,000 54,173,000 68,612,000    
Number of operating segment | Segments         1      
Accumulated deficit $ (60,442,512)   $ (60,442,512)   $ (59,263,550) $ (56,331,088)    
Warrant [Member]                
Restructuring Cost and Reserve [Line Items]                
Anti-dilutive common stock equivalents, excluded from the calculation of earnings per share | shares 22,041,000 11,375,000 22,041,000 11,375,000 22,241,000 32,292,000    
Stock Options [Member]                
Restructuring Cost and Reserve [Line Items]                
Anti-dilutive common stock equivalents, excluded from the calculation of earnings per share | shares 19,614,000 13,314,000 19,614,000 13,314,000 18,614,000 22,013,000    
Preferred share agreements [Member]                
Restructuring Cost and Reserve [Line Items]                
Anti-dilutive common stock equivalents, excluded from the calculation of earnings per share | shares 7,222,000 18,014,000 7,222,000 18,014,000 13,318,000 14,307,000    
Director [Member]                
Restructuring Cost and Reserve [Line Items]                
Interest rolled into principal         $ 30,000      
Patents [Member]                
Restructuring Cost and Reserve [Line Items]                
Amortization method of patents     Straight-line basis          
Patents [Member] | Europe [Member]                
Restructuring Cost and Reserve [Line Items]                
Number of patents granted | Patents         1      
Number of provisional patent applications pending | Patents         3      
Patents [Member] | US                
Restructuring Cost and Reserve [Line Items]                
Number of patents granted | Patents         10      
Trademarks [Member]                
Restructuring Cost and Reserve [Line Items]                
Number of patents granted | Patents         1      
Number of provisional patent applications pending | Patents         13      
Amortization method of patents     Straight-line basis          
Minimum [Member]                
Restructuring Cost and Reserve [Line Items]                
Estimated useful lives of property and equipment         5 years      
Minimum [Member] | Patents [Member]                
Restructuring Cost and Reserve [Line Items]                
Estimated lives of patents     17 years   17 years      
Maximum [Member]                
Restructuring Cost and Reserve [Line Items]                
Estimated useful lives of property and equipment         7 years      
Maximum [Member] | Patents [Member]                
Restructuring Cost and Reserve [Line Items]                
Estimated lives of patents     19 years   19 years